PSI Participates in Arab Health 2020 in Dubai
Once again Pharmaceutical Solutions Industry (PSI) , the largest sterile IV solutions manufacturer in the Middle East & North Africa (MENA) region, headquartered in Jeddah, Saudi Arabia, is all set to showcase a wide range of life saving solutions at the 45th edition of Arab Health event, which spans over four days from 27- 30 January 2020 at the Dubai World Trade Centre, Dubai, UAE.
PSI participation in such type of events is not sheer showcasing of products, but to make a genuine presence, with its exhibit booth to meet existing customers, agents and distributors from across the region, tap potential markets, provide access to life saving solutions, enhance key relationships with healthcare providers and boost the company’s image in the GCC and MENA region.
PSI Exhibit Booth # H3 – H19 is located in the Hall 3.
The exhibit booth features a full range of company’s products, and PSI is all ready to hold one-to-one meetings and business follow ups with prospective clients.
PSI is proud participant every year since 1994 at ‘Arab Health Exhibition & Conferences’, the largest gathering of healthcare companies, technology, products and services in the MENA region. And more than 55,000 healthcare and trade professionals and 4,250 exhibiting companies from over 64 countries are expected to participate 'Arab Health 2020', which runs from 10 AM to 6 PM.
Pharmaceutical Solutions Industry Ltd (PSI) a member of Ambah Group is the
leading sterile injectable manufacturer in Middle East and Africa.
Its manufacturing facilities in Saudi Arabia are GMP certified and equipped with the latest production technologies with over 40 years of proven reliable experience worldwide in contract manufacturing of parenteral solutions in plastic and glass bottles, plastic bags, as well as plastic ampoules.
In the recent past, Ambah/PSI has developed the first Ibuprofen intravenous (IV) infusion in the world (400mg/100ml). Successfully registered as Ambaprofen and Ambafen (Ibuprofen 400mg/100ml IV Infusion) through the health authorities in Germany, Spain, and Saudi Arabia, its patent has been granted by the European Patent Office (EPO patent no: 2636406) and United States Patent and Trademark Office (uspto Patent No: US 9351926 B2) for its dosage form with the approval of the European Medicines Agency (EMA).
To know more about Pharmaceutical Solutions
Industry (PSI), please visit at www.psiltd.com